Tirofiban Induced Thrombocytopenia: A Rare but Severe Adverse Effect.
Muhammad Shabbir RawalaAmna Saleem AhmedKanna PosinaVarun SundaramPublished in: Journal of community hospital internal medicine perspectives (2020)
With the advent of medical technology, coronary angiography is a common practice to evaluate patient for coronary artery disease. Normally, patients undergoing angiogram receive antiplatelets, anticoagulants, and platelet aggregation inhibitor agents. Glycoprotein IIb/IIIa receptor inhibitors are a type of platelets antiaggregant agents that can cause severe thrombocytopenia in very few cases. We present a case of a 69-year-old female who presented with chest pain, underwent an angiography and had two stents placed. She was administered tirofiban during angiogram that caused acute severe thrombocytopenia decreasing her platelets count from 224 to 2 k/mm3 within 1 day. Patients platelets gradually recovered after trial of steroid and platelets transfusion. Antiplatelets (Aspirin and Clopidogrel) were resumed; however, patient's platelets remained stable.
Keyphrases
- drug induced
- coronary artery disease
- patients undergoing
- early onset
- healthcare
- red blood cell
- end stage renal disease
- case report
- percutaneous coronary intervention
- ejection fraction
- newly diagnosed
- acute coronary syndrome
- antiplatelet therapy
- cardiovascular events
- liver failure
- clinical trial
- optical coherence tomography
- cardiovascular disease
- study protocol
- emergency department
- prognostic factors
- randomized controlled trial
- atrial fibrillation
- high glucose
- oxidative stress
- intensive care unit
- aortic stenosis
- phase ii
- diabetic rats
- binding protein